Literature DB >> 2446784

Phosphorylation determines two distinct species of Tau in the central nervous system.

S C Papasozomenos1, L I Binder.   

Abstract

The monoclonal antibody, Tau-1, which had previously been used to localize tau to the axonal compartment in brain has been reutilized for light and electron microscopic immunohistochemistry following phosphatase treatment of tissue. We report here that a significant quantity of tau in the central nervous system is phosphorylated in situ at or near the Tau-1 epitope, preventing the binding of the Tau-1 antibody. Upon removal of this/these phosphate group(s), however, Tau-1 was observed in the somatodendritic compartment of neurons as well as in axons. Furthermore, intense staining was also observed in astrocytes and in perineuronal glial cells. This immunoreactivity was present along the lengths of microtubules and on ribosomes (polysomes). Treatment of immunoblots of extracts of whole cerebral cortex with phosphatase confirmed the immunohistochemical results in that a 50-65% increase in Tau-1 binding to the tau region of the blot was noted. Moreover, a novel monoclonal antibody, Tau-2, was also used in these experiments. This antibody binds only to tau and localizes along microtubules in axons, somata, dendrites, and astrocytes and on ribosomes (polysomes) without phosphatase pretreatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446784     DOI: 10.1002/cm.970080303

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  121 in total

Review 1.  Tau protein function in axonal formation.

Authors:  G Paglini; L Peris; F Mascotti; S Quiroga; A Caceres
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

2.  Tau dephosphorylation at tau-1 site correlates with its association to cell membrane.

Authors:  M Arrasate; M Pérez; J Avila
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

Review 3.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

4.  Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.

Authors:  D W Dickson; H Ksiezak-Reding; W K Liu; P Davies; A Crowe; S H Yen
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

5.  Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer's disease. Demonstration using the hydrated autoclaving method.

Authors:  R W Shin; T Iwaki; T Kitamoto; Y Sato; J Tateishi
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

6.  Argyrophilic glial intracytoplasmic inclusions in multiple system atrophy: immunocytochemical and ultrastructural study.

Authors:  H Abe; S Yagishita; N Amano; K Iwabuchi; K Hasegawa; K Kowa
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

7.  Lack of ubiquitin immunoreactivities at both ends of neuropil threads. Possible bidirectional growth of neuropil threads.

Authors:  T Iwatsubo; M Hasegawa; Y Esaki; Y Ihara
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

8.  The role of tau phosphorylation in transfected COS-1 cells.

Authors:  M Medina; E Montejo de Garcini; J Avila
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

9.  Doxorubicin affects tau protein metabolism in human neuroblastoma cells.

Authors:  A Argasinski; H Sternberg; B Fingado; P Huynh
Journal:  Neurochem Res       Date:  1989-10       Impact factor: 3.996

10.  Immunohistochemical evidence for reorganization of tau in the plaques and tangles in Alzheimer's disease.

Authors:  J G Wood; P Zinsmeister
Journal:  Histochem J       Date:  1989-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.